Fig. 3From: IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimabOverall survival (A) and PFS (B) after immunotherapy with cemiplimab according to the serum level of IL-6 at baseline, in patients naïve to immunotherapyBack to article page